Cancer – PLAT-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR T-cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma

What is the goal of this study?

PLAT-05 is one of the first-in-the-nation pediatric phase 1 trials that tests the safety and feasibility of CAR T cells that have been reprogrammed to target CD19 and CD22 proteins simultaneously. CD19 and CD22 are expressed by most leukemia cells. 

Our researchers developed PLAT-05 as an investigational treatment option that will hopefully lead to long-term remission for patients whose cancer expresses CD19 and CD22.

Learn how CAR T-cell therapy works. 

Who can join the study?

This study might be a good fit for children and young adults who:

• Are ages 1 to 26 years old
• Have relapsed or refractory pre-B acute lymphoblastic leukemia (ALL) or other CD19+ or CD22+ acute leukemia or CD19+ non-Hodgkin lymphoma. It is not open to young people with other leukemias or other childhood cancers.

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What will happen if my child takes part in this study?

You can read more about the PLAT-05 study on clinicaltrials.gov.

Who can I contact for more information?

Please email or call us at 206-987-2106 to learn more about the study.